Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EBT (2020 - 2025)

Historic EBT for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $216.3 million.

  • Apellis Pharmaceuticals' EBT rose 48048.48% to $216.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.7 million, marking a year-over-year increase of 11883.8%. This contributed to the annual value of -$196.7 million for FY2024, which is 6263.68% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported EBT of $216.3 million as of Q3 2025, which was up 48048.48% from -$41.7 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' EBT's 5-year high stood at $216.3 million during Q3 2025, with a 5-year trough of -$219.2 million in Q2 2021.
  • Moreover, its 5-year median value for EBT was -$137.7 million (2022), whereas its average is -$107.3 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' EBT plummeted by 22226.69% in 2021, and later soared by 48048.48% in 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' EBT (Quarter) stood at -$147.6 million in 2021, then decreased by 13.47% to -$167.5 million in 2022, then soared by 47.96% to -$87.2 million in 2023, then soared by 58.62% to -$36.1 million in 2024, then surged by 699.76% to $216.3 million in 2025.
  • Its last three reported values are $216.3 million in Q3 2025, -$41.7 million for Q2 2025, and -$91.9 million during Q1 2025.